Liraglutide treatment appeared to be synergistic with buprenorphine, as reported by STAT: Among patients already on buprenorphine, a medication approved by the FDA to treat opioid use disorder, those also on liraglutide were more likely to report zero cravings than the placebo group
Behavioural interventions remain foundational , and pharmacotherapy should complement rather than replace lifestyle modifications
Injecting untested, unregulated peptides is, at best, a large waste of money and, at worst, a path to long-term side effects that we do not yet understand
It likely works by curbing your appetite and helping you eat less, though the exact way it influences weight isnt fully clear
GLP-1 receptor agonists, when used under medical supervision, are typically titrated over 16 to 20 weeks to reach the target dose, producing a more gradual weight loss trajectory